Kairos Pharma, Ltd.
General ticker "KAPA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $16.5M (TTM average)
Kairos Pharma, Ltd. does not follow the US Stock Market performance with the rate: -25.7%.
Estimated limits based on current volatility of 5.3%: low 0.36$, high 0.40$
Factors to consider:
- Total employees count: 4 as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: No approved products, Operational and conduct risks, Labor/talent shortage/retention, Market competition, Regulatory and compliance
- Current price 28.6% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.52$, 1.42$]
- 2026-12-31 to 2027-12-31 estimated range: [0.49$, 1.33$]
Short-term KAPA quotes
Long-term KAPA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $1.71MM | $2.34MM | $5.57MM |
| Operating Income | $-1.71MM | $-2.34MM | $-5.57MM |
| Non-Operating Income | $-0.10MM | $-0.26MM | $0.12MM |
| Interest Expense | $0.04MM | $0.04MM | $0.00MM |
| R&D Expense | $0.08MM | $0.41MM | $2.13MM |
| Income(Loss) | $-1.81MM | $-2.60MM | $-5.45MM |
| Net Income(Loss)* | $-1.81MM | $-2.60MM | $-5.45MM |
| Stockholders Equity | $-2.08MM | $4.78MM | $6.34MM |
| Assets | $0.96MM | $5.77MM | $6.54MM |
| Operating Cash Flow | $0.08MM | $-3.96MM | $-3.44MM |
| Financing Cash Flow | $-0.42MM | $5.13MM | $6.66MM |
| Earnings Per Share** | $-0.17 | $-0.23 | $-0.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.